Group 1 - The core point of the article is that Zhonghui Biotech-B (02627) has seen a significant stock price increase following the approval of its quadrivalent influenza virus subunit vaccine by the National Medical Products Administration of China, marking it as the first and only vaccine of its kind approved for the entire population in China [1][2] - The stock price rose over 8%, with a current increase of 7.49%, reaching HKD 51.25, and a trading volume of HKD 18.463 million [1] - The quadrivalent influenza virus subunit vaccine is a major upgrade from traditional virus split vaccines, offering comprehensive protection, high purity of antigen components, and lower risk of adverse reactions [1] Group 2 - The vaccine developed by Zhonghui Biotech-B utilizes a third-generation technology route, optimizing production processes to extract only effective antigen components—hemagglutinin (HA) and neuraminidase (NA)—which significantly enhances antigen purity and reduces impurity content [2] - This new vaccine is expected to fill a market gap as it is the only vaccine product included in the preliminary review list for innovative drugs under commercial insurance in China [1][2]
中慧生物-B涨超8% 四价流感病毒亚单位疫苗入选商保初步审查名单 市场稀缺性显著